Product Information
SIROLIMUS 0.5 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.8415 per EA under NDC 59762100101. Its NADAC has been published 650 times since Apr 23, 2014.
FDA first approved this application on Aug 25, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762100101
Classification
Generic
Dosage Form
TABLET, SUGAR COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SIROLIMUSApproval Type
Authorized Generic (NDA)
FDA Application
NDA021110FDA Approved
8/25/2000
TE Code
AB
On Market Since
1/7/2014
Pharmacological Classes
Price Statistics
The NADAC for SIROLIMUS 0.5 MG TABLET has been published 650 times since Apr 23, 2014, and over the history we have for it it has declined 86.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8415 per EA |
|---|---|
| All-time high | $6.5979 (Feb 15, 2017) |
| All-time low | $0.8415 (Sep 23, 2026) |
| 52-week high | $1.8025 |
| 52-week low | $0.8415 |
| Median price | $5.2645 |
| Average price | $4.6763 |
| Largest weekly change | -50.5% (Sep 20, 2023) |
| Weeks tracked | 650 |
| Tracking since | Apr 23, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the SIROLIMUS market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
SIROLIMUS market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SIROLIMUS 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SIROLIMUS 0.5 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.8415 per EA (NDC 59762100101), effective Sep 30, 2026.
How has the price of SIROLIMUS 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for SIROLIMUS 0.5 MG TABLET has declined 86.5%. It has been tracked across 650 weekly CMS publications since Apr 23, 2014.
What are the highest and lowest recorded NADAC prices for SIROLIMUS 0.5 MG TABLET?
Since Apr 23, 2014, the NADAC for SIROLIMUS 0.5 MG TABLET has ranged from a low of $0.8415 (Sep 23, 2026) to a high of $6.5979 (Feb 15, 2017), with a median of $5.2645 per EA.
Are there cheaper alternatives to SIROLIMUS 0.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of SIROLIMUS 0.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SIROLIMUS 0.5 MG TABLET?
SIROLIMUS 0.5 MG TABLET (NDC 59762100101) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.